Increased intracellular glutathione (GSH) levels as well as increased activity of GSH-dependent enzymes have been associated with multidrug resistance in some studies, whereas others have failed to find evidence for a role of GSH or its dependent enzymes in multidrug resistance (reviewed in Moscow and Dixon, 1993) . However, several studies have shown that treatment of cells with buthionine sulphoximine (BSO), an inhibitor of y-glutamylcysteine synthetase, results in the depletion of intracellular glutathione and increased sensitivity of cells to several drugs, including melphalan, anthracycines and etoposide (Green et al., 1984; Hamilton et al., 1985; Dusre et al., 1989; Lutzky et al., 1989; Mans et al., 1992) . Studies with doxorubicin-resistant HL60 cells (HL60/AR) have demonstrated that BSO treatment enhances the sensitivity of the resistant cells to the anthracycline daunorubicin and that this is accompanied by an increase in intracellular drug accumulation and retention (Lutzky et al., 1989; Gollapudi and Gupta, 1992) . Similar results have also been reported with unselected drug-sensitive human lung, ovarian and breast carcinoma cells (Mans et al., 1992) . In contrast, BSO treatment does not enhance doxorubicin sensitivity in multidrug-resistant small-cell lung cancer H69AR cells, despite GSH depletion (Cole et al., 1990) . Thus,. although pharmacological depletion of GSH results in sensitisation of some cells to cytotoxic drugs, it is unclear whether this is a direct consequence of GSH depletion or whether the two effects occur independently.
A doxorubicin-selected, multidrug-resistant MCF7 human breast carcinoma cell line (MCF7/ADR) with increased GSH S-transferase levels that exhibits significant cross-resistance to etoposide has been described (Batist et al., 1986) , suggesting that GSH-mediated mechanisms might contribute to etoposide resistance. However, these cells also highly overexpress MDR1, which can also result in cross-resistance to etoposide. We have recently described a VP-16-selected, multidrugresistant MCF7 subline (MCF7/VP) that does not express MDR1 mRNA, but instead contains 15-fold elevated levels of mRNA for the multidrug resistance-associated protein MRP (Schneider et al., 1994) . These cells are 30 to 60-fold resistant to VP-16, 9-fold resistant to doxorubicin and 5-to 15-fold resistant to vincristine, and resistance is, at least in part, due to a reduction in intracellular drug concentrations. In the present study we examined the effects of BSO treatment on the drug sensitivity of MCF7/VP cells. These studies demonstrated that BSO pretreatment resulted in greater sensitivity of MCF7/VP cells to VP-16 and vincristine and that chemosensitisation is associated with an increase in intracellular drug accumulation.
Drug uptake, efflux and protein binding Drug uptake and efflux studies were done essentially as described previously (Schneider et al., 1994 Table II show that GSH levels in resistant MCF7/VP cells were approximately 25% lower than in sensitive MCF7/WT cells and that they were further reduced by 50-60% in MCF7/VP cells after continuous treatment with 2.5 m BSO for 5 days. This result suggested that the sensitisation of MCF7/VP cells by BSO may be mediated through the depletion of GSH. To further study this possibility, cells were preincubated with 50 tLM BSO for 24 h which resulted in an 80-90% reduction in GSH levels in both cell lines (Table II) . When cells were preincubated for 24 h in the presence of 50 SAM BSO, followed by 24 h coincubation with 50 ;M BSO and VP-16, MCF7/VP cells excluded. Furthermore, following BSO treatment total retained radioactivity after 1 h in both cell lines was not significantly increased. In contrast, a statistically significant increase (35%, P = 0.04) in acid-precipitable VP-16 was detected in MCF7/VP cells, whereas the amount of tightly bound drug remained unchanged in MCF7/WT cells after BSO treatment (Figure 4 ).
Discussion
Chemosensitisation of cells by BSO is generally associated with glutathione depletion and is thought to be related to changes in the metabolism of cytotoxic drugs. However, some studies have also examined the possible effect of BSO on drug accumulation and/or intracellular drug distribution. For example, Lutzky et al. (1989) investigated the effect of BSO on glutathione and drug levels as well as on intracellular drug distribution in a doxorubicin-resistant HL60 cell line, HL60/AR, which has been shown to overexpress p190, the product of the MRP gene (Marquardt et al., 1990; Krishnamachary and Center, 1993 efflux. Rather, pretreatment of the resistant cells with BSO was required in order for BSO to affect drug accumulation. Although the BSO-mediated increase in drug accumulation was accompanied by increased drug-mediated growth inhibition and GSH depletion in MCF7/VP cells, only minimally higher drug levels and drug sensitivity were observed in MCF7/WT cells, despite similar GSH depletion (Table III) . These results suggest that GSH depletion may be necessary but not sufficient for increased drug sensitivity and accumulation. However, MCF7/VP cells contained lower basal levels of GSH than the parental MCF7/WT cells, suggesting that, in addition to decreased drug accumulation, resistance in MCF7/VP cells may also be associated with lower GSH levels. Similarly, decreased GSH levels were also noted in drug-resistant HL60/AR and H69AR cells, both of which had GSH levels 2-to 6-fold lower than their drug-sensitive parental cell lines (Lutzky et al., 1989; Cole et al., 1990 (1987a, b) have shown that metabolites of VP-16 can covalently bind to proteins and DNA, and it was suggested that the bound metabolites are reactive and potentially damaging and capable of causing cellular injury and cell death. Thus, it is possible that the relative increase in acid-precipitable VP-16 in MCF7/VP cells after BSO treatment was, at least in part, responsible for the increased cytotoxicity. The non-effluxable pool of VP-16 in sensitive MCF7/WT cells was 3-fold higher than that in resistant MCF7/VP cells (135 ± 10 vs 47 ± 2 pmol of bound VP-16 per mg of protein for sensitive and resistant cells respectively). A similar difference was also observed in HL60 and HL60/AR cells (Politi and Sinha, 1989 Gollapudi and Gupta (1992) measured the effect of BSO on plasma membrane potential in HL60 and HL60/AR cells they were unable to detect any alterations, although the concentration of BSO and the time of exposure used in these experiments is unclear. Thus, it is not clear whether BSO can directly affect the plasma membrane. In contrast, Lutzky et al. (1989) suggested in their study that BSO might have affected intracellular distribution of GSH/ GST, which in turn may have led to increased drug accumulation and retention. Whether these two effects were related or independent remained unanswered. We have at present no evidence that either of these potential mechanisms contributed to the BSO-mediated chemosensitisation of MCF7/ VP cells.
It was recently suggested that the multidrug resistanceassociated protein (MRP), which is overexpressed in the MCF7/VP cells, functions as an efflux pump for glutathioneconjugated compounds (GS-X) (Ishikawa, 1992; Jedlitschky et al., 1994) . Thus, one might expect that depletion of GSH would lead to a reduction in the amount of conjugated substrate for GS-X and consequently result in higher intracellular drug concentrations. However, it is unclear if such a mechanism is responsible for the observed sensitisation of MCF7/VP cells by BSO, since neither VP-16 nor vincristine is a substrate for GSH conjugation (Tew, 1994) .
In conclusion, we have shown that BSO is able to sensitise resistant MCF7/VP cells and that this effect is mediated through an increase in intracellular drug concentration. Our results suggest that GSH depletion may be necessary but not sufficient for increased drug sensitivity and accumulation. In addition, increased drug binding in the resistant cells may also contribute to their sensitisation. However, additional experiments are required to define further the mechanism(s) involved in BSO-mediated chemosensitisation of MCF7/VP cells.
